United States : Mercks KEYTRUDA (pembrolizumab) Demonstrated Significant Improvement in Distant Metastasis-Free Survival (DMFS) Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase 3 KEYNOTE-716 Trial.
In: Mena Report, 2022-03-14
Online
Zeitungsartikel
Zugriff:
Titel: |
United States : Mercks KEYTRUDA (pembrolizumab) Demonstrated Significant Improvement in Distant Metastasis-Free Survival (DMFS) Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase 3 KEYNOTE-716 Trial.
|
---|---|
Link: | |
Zeitschrift: | Mena Report, 2022-03-14 |
Veröffentlichung: | 2022 |
Medientyp: | Zeitungsartikel |
ISSN: | 2219-0112 (print) |
Sonstiges: |
|